Cancer Chemotherapy, Theoretical Foundations of
189
Papandreou, C., Daliani, D., Millikan, R.E., et al.
(2001) Phase I study of intravenous (I.V.)
proteasome inhibitor PS-341 in patients (Pts)
with advanced malignancies,
Proc. Am. Soc.
Clin. Oncol.
20
, 86a.
Plumb, J.A.,
Finn, P.W.,
Williams, R.J.,
et al.
(2003)
Inhibition
of
human
tumour
cell
growth
by
the
novel
histone
deacetylase
inhibitor
PXD101,
Mol.
Cancer
Ther.
2
,
721–728.
Scheibel, T.,
Buchner, J.
(1998)
The
Hsp90
complex – a super-chaperone machine as a
novel drug target,
Biochem. Pharmacol.
56
,
675–682.
Seidman, A.D., Fornier, M.N., Esteva, F.J., et al.
(2001) Weekly trastuzumab and paclitaxel
therapy
for
metastatic
breast
cancer
with
analysis
of
ef±cacy
by
HER2
immunophenotype and gene ampli±cation,
J. Clin. Oncol.
19
, 2587–2595.
Selivanova, G.,
Ryabchenko, L.,
Jansson, E.,
Iotsova, V., Wiman, K.G. (1998) Reactivation
of mutant p53: a new strategy for cancer
therapy,
Semin. Cancer Biol.
8
, 369–378.
Sgouros,
G.,
Yang,
W.-H.,
Richon,
V.M.,
Kelly, W.K., Rifkind, R.A., Marks, P.A. (2002)
Synergistic
interaction
of
suberoylanillde
hydroxamic acid (SAHA) and radiation in
human prostate tumour spheroids,
Proc. Am.
Soc. Clin. Oncol.
2
, 105.
Sherr, C.J., Roberts, J.M. (1999) CDK inhibitors:
positive
and
negative
regulators
of
cyclin-dependent
regulators
of
G1-phase
progression,
Genes Dev.
13
, 1501–1512.
Slamon, D.J., Leyland-Jones, B., Shak, S., et al.
(2001) Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast
cancer that over-expresses HER2,
N. Engl. J.
Med.
344
, 783–792.
Stancato, L.F., Silverstein, A.M., Owens-Grillo,
J
.K
.
,Chow
,Y
.H
.
,Jove
,R
.
,Pra
t
t
,W
.B
.(1997
)
.
The hsp90-binding antibiotic geldanamycin
decreases Raf levels and epidermal growth
factor signaling without disrupting formation
of signaling complexes or reducing the speci±c
enzymatic activity of Raf kinase,
J. Biol. Chem.
272
, 4013–4020.
Stinchcombe,
T.E.,
Mitchell,
B.S.,
Depcik-
Smith, N., et al. (2000) PS-341 is active in
multiple myeloma: preliminary report of a
phase I trial of the proteasome inhibitor PS-341
in patients with hematologic malignancies,
Blood
96
, 516a.
Strahl, B.D., Allis, C.D. (2000) The language of
covalent histone modi±cations,
Nature
403
,
41–45.
Srethapakdi, M., Liu, F., Tavorath, R., Rosen, N.
(2000)
Inhibition
of
Hsp90
function
by
ansamycins
causes
retinoblastoma
gene
product-dependent G1 arrest,
Cancer Res.
60
,
3940–3946.
Stebbins,
C.E.,
Russo,
A.A.,
Schneider,
C.,
Rosen, N., Hartl, F.U., Pavletich, N.P. (1997)
Crystal structure of an Hsp90-geldanamycin
complex: targeting of a protein chaperone by
an antitumour agent,
Cell
89
, 239–250.
Thomas, J.P.,
Tutsch, K.D.,
Cleary, J.F.,
et al.
(2002) Phase I clinical and pharmacokinetic
trial of the cyclin-dependent kinase inhibitor
flavopiridol,
Cancer Chemother. Pharmacol.
50
,
465–472.
Van Oosterom, A.T., Judson, I., Verweij, J., et al.
(2001) STI571, an active drug in metastatic
gastrointestinal stromal tumours (GIST), an
EORTC Phase 1 study,
Proc. Am. Soc. Clin.
Oncol.
20
,1a.
Xu, Y., Lindquist, S. (1997) Heat-shock protein
hsp90
governs
the
activity
of
pp60v-src
kinase,
P
r
o
c
.N
a
t
l
.A
c
a
d
.S
c
i
.U
.
S
.
A
.
90
,
7074–7078.
Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goed-
del, D.V., Baldwin, A.S. Jr. (1998) NF-KB anti
apoptosis: induction of TRAF1 and TRAF2
and c-IAP1 and c-IAP2 to suppress caspase 8
activation,
Science
281
, 1680–1683.
W
u
,L
.
,T
i
m
m
e
r
s
,C
.
,M
a
i
t
i
,B
.
,e
t
a
l
.
(2001) The E2F1-3 transcription factors are
essential for cellular proliferation,
Nature
414
,
457–462.
Zagzag, D., Zhong, H., Scalzitti, J.M., Laugh-
ner, E., Simons, J.W., Semenza, G.L. (2000)
Expression of hypoxia inducible factor 1
α
in
brain tumours: association with angiogen-
esis, invasion, and progression,
Cancer
88
,
2606–2618.
Zhong, H., Chiles, K., Feldser, D., et al. (1999)
Over-expression of hypoxia-inducible factor
1
α
in common human cancers and their
metastases,
Cancer Res.
59
, 5830–5835.
Zhong, H., De Marzo, A.M., Laughner, E., et al.
(2000) Modulation of HIF1
α
expression by the
epidermal growth factor phosphatidylinositol
3
kinase/PTEN/AKT/FRAP
pathway
in
human prostate cancer cells: implications for
tumour angiogenesis and therapeutics,
Cancer
Res.
60
, 1541–1545.
previous page 863 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 865 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off